Universal Biosensors, Inc
(ASX:UBI) has obtained FDA approval to sell in the United States a device called the Xprecia Stride Analyzer.
This is a handheld device used to quickly and accurately monitor and assess patients who taking oral anticoagulation therapy warfarin.
The device was produced by Universal’s partner, Siemens Healthineers, and uses test strips, which were developed and manufactured by Universal Biosensors.
The company says that the Xprecia Stride Analyzer was launched commercially in Europe in May, last year and won numerous design awards.
The company says the worldwide point-of-care market for coagulation testing was worth around US$1 billion in 2014, and is forecast to grow by 9% each year.
Universal Biosensors posted a net loss of $1.2 million at 30 June 2016.
